Precision BioSciences Inc. (NASDAQ:DTIL) shares traded -12.38% lower at $0.46 on Wall Street last session.
DTIL stock price is now -24.07% away from the 50-day moving average and -51.72% away from the 200-day moving average. The market capitalization of the company currently stands at $53.39M.
With the price target of $7, BMO Capital Markets recently initiated with Outperform rating for Precision BioSciences Inc. (NASDAQ: DTIL).
In other news, Scimeca Dario, General Counsel and Secretary sold 13,361 shares of the company’s stock on Jun 08. The stock was sold for $10,021 at an average price of $0.75. Upon completion of the transaction, the General Counsel and Secretary now directly owns 68,473 shares in the company, valued at $31497.58. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 27, Chief Medical Officer List Alan sold 7,771 shares of the business’s stock. A total of $6,139 was realized by selling the stock at an average price of $0.79. This leaves the insider owning 56,496 shares of the company worth $25988.16. Insiders disposed of 100,782 shares of company stock worth roughly $46359.72 over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DTIL stock. A new stake in Precision BioSciences Inc. shares was purchased by NATIXIS during the first quarter worth $11,000. WADE G W & INC invested $6,000 in shares of DTIL during the first quarter. In the first quarter, 626 FINANCIAL, LLC acquired a new stake in Precision BioSciences Inc. valued at approximately $6,000. CUBIST SYSTEMATIC STRATEGIES, LLC acquired a new stake in DTIL for approximately $5,000. In total, there are 114 active investors with 47.40% ownership of the company’s stock.
Precision BioSciences Inc. (NASDAQ: DTIL) opened at $0.5100 on Thursday. During the past 12 months, Precision BioSciences Inc. has had a low of $0.47 and a high of $2.05. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 2.60, and a quick ratio of 2.60. The fifty day moving average price for DTIL is $0.5988 and a two-hundred day moving average price translates $0.9480 for the stock.
The latest earnings results from Precision BioSciences Inc. (NASDAQ: DTIL) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.24 by 0.14. This compares to -$0.46 EPS in the same period last year. The company reported revenue of $19.79 million for the quarter, compared to $3.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 418.04 percent. For the current quarter, analysts expect DTIL to generate $7M in revenue.
Precision BioSciences Inc.(DTIL) Company Profile
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
